Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma

Inclusion Criteria: * Histologically/cytologically confirmed soft tissue sarcoma of gynecologic tract including 1 of the following subtypes: uterine leiomyosarcoma, malignant mixed mullerian tumor/carcinosarcoma, disease originating in ovary/fallopian tube allowed * Locally advanced/unresectable/metastatic disease * Previously treated disease must have radiographic/clinical evidence of PD * Measurable disease-at least 1 lesion in at least 1 dimension (longest diameter) as \>=20mm with conventional techniques or as \>=10mm with spiral CT scan * Indicator lesions may not have been previously treated with surgery/radiotherapy/radiofrequency ablation unless PD has been confirmed * ECOG PS 0-2 OR Karnofsky PS 60-100% * Life expectancy\>=3 months * WBC\>=3,000/mm\^3 * Absolute neutrophil count\>=1,500/mm\^3 * Platelet count\>=75,000/mm\^3 * Bilirubin=\<1.5xULN * AST and ALT=\<3xULN * INR=\<1.5 (unless on warfarin) * Creatinine=\<1.5xULN OR creatinine clearance\>=60 mL/min * Urine protein\<1+ by dipstick OR 24-hour urine protein\<500 mg OR urine protein:creatinine ratio\<1 * Not pregnant/nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for ≥6 months after treatment - No other active malignancy within past 5 years except adequately treated cervical carcinoma in situ/nonmelanoma skin cancer * No known hypersensitivity to Chinese hamster ovary cell products/other recombinant human antibodies * No history of allergic reactions attributed …